← Back to patent-cliff list
Tirbanibulin
Tier C — Watch / tradeTirbanibulin
Athenex Inc
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Tubulin, SRC
Brand：Klisyri, KLISYRI
Indications (approved)：Actinic keratosis
Regional status
US
Approved
2020-12-14
EU
Approved
2021-07-16
China
-
Japan
Phase III
2021-12-21
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tirbanibulin?
Approved indications include: Actinic keratosis.
When does the Tirbanibulin patent expire?
No public expiry year is available for Tirbanibulin yet; this page updates once verified.
How do I get a quote for Tirbanibulin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27